Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Healthcare IT Today
JANUARY 8, 2024
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. It is key for pharmaceutical companies to recognize that efficiency does not override compliance, patient safety or regulatory standards.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT Today
NOVEMBER 7, 2023
A recent Deloitte study estimates the average cost of developing a single new drug at $2.3 This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials.
Society for Participatory Medicine
FEBRUARY 1, 2023
The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. By the power vested in clinical research, the FDA now pronounces us patient and industry. You may now kiss the cancer survivor.
Digital Health Global
JANUARY 8, 2024
Top-10 global pharmaceutical companies are already benefiting from Medable’s novel technology, shaving weeks off build times. Medable’s new AI and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster.
Healthcare IT Today
JANUARY 9, 2023
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. This is not sustainable when so many of the active pharmaceutical ingredients and medical device components we rely on come from a small handful of countries.
Digital Health Global
APRIL 16, 2024
The Phase IV trial, funded by a top-10 global pharmaceutical company, had a narrow recruitment window to enroll patients suffering from Anemia in End Stage Kidney Disease (ESKD) across more than 40 dialysis centers, involving 476 site users. .–(BUSINESS WIRE)– Medable Inc. , Renal Care ’s (USRC) investigator-initiated trial.
Expert insights. Personalized for you.
167 
Let's personalize your content